Prognostic Value of Circulating Tumor Cells in Patients With Locally Advanced and Metastatic/Recurrent Head and Neck Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Recurrence
- Sponsor
- Chang Gung Memorial Hospital
- Enrollment
- 53
- Locations
- 1
- Primary Endpoint
- Progression-free survival
- Status
- Terminated
- Last Updated
- 10 years ago
Overview
Brief Summary
We hypothesized that the number of circulating tumor cells (CTCs) and molecular markers on CTCs could be a prognostic factor or predictive factor to patients with head neck cancer.
Detailed Description
1. Histologically or cytopathologically proven head and neck squamous cell carcinoma (HNSCC) 2. Disease status: locally advanced or recurrent/metastasized at initial presentation 3. Age \>=20 years old 4. Could understand and signed the informed consents of this study 5. Enrolled patients were classified into three distinct subgroups: 1. Patients underwent curative surgery followed by adjuvant chemoradiotherapy (CRT) because of some pathologic features such as positive margin, pathologic N2, and extracapsular spread (ECS) of involved lymph nodes indicating early relapse according to recommendation from National Comprehensive Cancer Network(NCCN) guidelines; 2. Patients with advanced disease directly underwent definitive concurrent chemoradiotherapy(CCRT); 3. Patients were to have palliative chemotherapy for existence of distant metastasis or poor general condition for definitive CCRT. 6. Blood samples were collected within 7 days before the first dose of chemotherapy.
Investigators
Eligibility Criteria
Inclusion Criteria
- •histologically or cytopathologically proven head and neck squamous cell carcinoma Age ≥ 20 years. Measurable or evaluable disease according to Response Evaluation Criteria In Solid Tumors(RECIST) criteria.
- •Ability to sign informed consent.
Exclusion Criteria
- •Prior cancers within 5 years, except for non-melanoma skin cancers, and in situ cervical cancers.
- •Inability to comply with study and/or follow-up procedures.
Outcomes
Primary Outcomes
Progression-free survival
Time Frame: one year
Measure response or progression events via all available imaging studies, including Chest-Xray, CT scans, or MRI, PET study. The relationship between CTCs number and time from CTCs checkpoint to disease progression will be analyzed.